# Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia

> **NCT03172702** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 150 (actual)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** Zirconium Cyclosilicate

## Key facts

- **NCT ID:** NCT03172702
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-04
- **Primary completion:** 2019-07-06
- **Final completion:** 2019-07-06
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172702, "Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03172702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*